US Patent Issued to Takeda Pharmaceutical on Aug. 19 for "Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies" (Illinois, Massachusetts, Tennessee Inventors)

ALEXANDRIA, Va., Aug. 20 -- United States Patent no. 12,391,765, issued on Aug. 19, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies" was invented by Glennda Smithson (Antioch, Ill.), Jose Estevam (Quincy, Mass.) and Nicholas Jones (LaVergne, Tenn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to anti-CD38 antibodies and their use as therapeutics and diagnostics. The present disclosure further relates to methods of treating autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis. The present disclosure further relates to diagnostic assay me...